Several anti-HGF/c-MET antibodies, such as onartuzumab, tepotinib, capmatinib, and tivantinib are already in the clinical stage of HCC treatment evaluation (NCT01897038, NCT02115373, NCT01737827, NCT02029157). Here, MET is linked to hepatocellular carcinoma.